Literature DB >> 16103885

Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions.

Malte Buchholz1, Mike Braun, Anna Heidenblut, Hans A Kestler, Günter Klöppel, Wolff Schmiegel, Stephan A Hahn, Jutta Lüttges, Thomas M Gress.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumours. Both the late clinical presentation of patients, due to lack of early symptoms, as well as the rapid and aggressive course of the disease contribute to the extremely high mortality of this malignancy. Recently, a multistep progression model for PDAC integrating morphological, clinical and molecular evidence has been proposed. Putative precursor lesions, termed pancreatic intraepithelial neoplasia (PanIN), are classified into three different grades (PanIN-1 through -3) based on the degree of cellular atypia they display. We have conducted large-scale expression profiling analyses of microdissected cells from normal pancreatic ducts, PanINs of different grades and PDACs using whole-genome oligonucleotide microarrays. Verification of hybridisation results for selected genes was performed using quantitative real-time PCR and immunohistochemical analyses on PanIN tissue microarrays. Comparison of the expression profiles demonstrated that the greatest changes in gene expression occur between PanIN stages 1B and 2, suggesting that PanIN-2 may represent the first truly preneoplastic stage in PDAC progression. Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early diagnosis of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the pancreas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103885     DOI: 10.1038/sj.onc.1208804

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  94 in total

1.  Identification of germline genomic copy number variation in familial pancreatic cancer.

Authors:  Wigdan Al-Sukhni; Sarah Joe; Anath C Lionel; Nora Zwingerman; George Zogopoulos; Christian R Marshall; Ayelet Borgida; Spring Holter; Aaron Gropper; Sara Moore; Melissa Bondy; Alison P Klein; Gloria M Petersen; Kari G Rabe; Ann G Schwartz; Sapna Syngal; Stephen W Scherer; Steven Gallinger
Journal:  Hum Genet       Date:  2012-06-05       Impact factor: 4.132

2.  COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion.

Authors:  Bart van de Sluis; Xicheng Mao; Yali Zhai; Arjan J Groot; Jeroen F Vermeulen; Elsken van der Wall; Paul J van Diest; Marten H Hofker; Cisca Wijmenga; Leo W Klomp; Kathleen R Cho; Eric R Fearon; Marc Vooijs; Ezra Burstein
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

3.  A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.

Authors:  Seetharaman Balasenthil; Nanyue Chen; Steven T Lott; Jinyun Chen; Jennifer Carter; William E Grizzle; Marsha L Frazier; Subrata Sen; Ann McNeill Killary
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

4.  Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays.

Authors:  T Harada; C Chelala; V Bhakta; T Chaplin; K Caulee; P Baril; B D Young; N R Lemoine
Journal:  Oncogene       Date:  2007-10-22       Impact factor: 9.867

5.  LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer.

Authors:  Kohei Nakata; Kenoki Ohuchida; Eishi Nagai; Akifumi Hayashi; Yoshihiro Miyasaka; Tadashi Kayashima; Jun Yu; Shinichi Aishima; Yoshinao Oda; Kazuhiro Mizumoto; Masao Tanaka; Masazumi Tsuneyoshi
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

6.  Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.

Authors:  S Bonner-Weir; P A In't Veld; G C Weir
Journal:  Diabetes Obes Metab       Date:  2014-01-29       Impact factor: 6.577

7.  Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.

Authors:  Amel Saadi; Nicholas B Shannon; Pierre Lao-Sirieix; Maria O'Donovan; Elaine Walker; Nicholas J Clemons; James S Hardwick; Chunsheng Zhang; Madhumita Das; Vicki Save; Marco Novelli; Frances Balkwill; Rebecca C Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

8.  Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.

Authors:  Vijaya Ramachandran; Thiruvengadam Arumugam; Huamin Wang; Craig D Logsdon
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.

Authors:  Ru Chen; Sheng Pan; Xiaobo Duan; Brad H Nelson; Rob A Sahota; Sarah de Rham; Richard A Kozarek; Martin McIntosh; Teresa A Brentnall
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

Review 10.  A compendium of potential biomarkers of pancreatic cancer.

Authors:  H C Harsha; Kumaran Kandasamy; Prathibha Ranganathan; Sandhya Rani; Subhashri Ramabadran; Sashikanth Gollapudi; Lavanya Balakrishnan; Sutopa B Dwivedi; Deepthi Telikicherla; Lakshmi Dhevi N Selvan; Renu Goel; Suresh Mathivanan; Arivusudar Marimuthu; Manoj Kashyap; Robert F Vizza; Robert J Mayer; James A Decaprio; Sudhir Srivastava; Samir M Hanash; Ralph H Hruban; Akhilesh Pandey
Journal:  PLoS Med       Date:  2009-04-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.